A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

This is a single-arm, open-label, phase I dose-escalation clinical study to evaluate the safety and preliminary efficacy of CLL1 and CD38 dual-target CAR T cell injection in r/r AML subjects.

Trial Details

NCT ID
NCT06880354
Phase
PHASE1
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • CLL1 and CD38 Dual-Target CAR-T Cell Injection
Locations (sample)
  • Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

  • At the time of signing the informed consent, 18-70 years old (including the critical value);
  • Diagnosed with acute myeloid leukemia (except for APL) based on the World Health Organization (WHO) 2022 criteria and meeting the diagnostic criter…
  • Positive expression of CLL1 and/or CD38 in tumor cells;
  • Estimated survival ≥3 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →